

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Docket No. API-03-03-PCT-US)

In the Application of:)
)
 Berinstein, et al.)
) **Examiner: Jeffrey E. Russel**
Serial No. 10/553,137)
) **Art Unit: 1654**
Filing Date: Feb. 25, 2008)
)
Title: TUMOR ANTIGENS BFA5 FOR)
 PREVENTION AND/OR)
 TREATMENT OF CANCER)

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Transmitted via EFS-Web

Information Disclosure Statement Under 37 CFR 1.97(c)

Applicants respectfully submit this Information Disclosure Statement, PTO-SB08a, and copies of the non-U.S. patent references cited therein. This Information Disclosure Statement is in compliance with the duty of candor as set forth in 37 C.F.R. § 1.56. The Applicant believes no fees are due with this submission; if this is in error, the undersigned hereby authorizes the Commissioner to deduct any required fees from Deposit Account No. 50-0244. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing of the present application.

In the judgment of the undersigned, portions of the references may be material to the examination of the pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the references. This Statement is not a representation that the cited references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. §102 or §103.

CITED REFERENCES

U.S. patents and published applications

6,969,518
2004/0223949A1
2006/0154291A1
2007/0128655A1

Non-U.S. Patent Documents

WO 2004/092212A3
WO 01/47959A

Other Documents

Jager, et al. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. *Cancer Immunity*, vol. 2, p. 12 (2002)

Jager, et al. Identification of a Tissue-specific Putative Transcription Factor in Breast Tissue by Serological Screening of a Cancer Library. *Cancer Research*, 61: 2055-2061 (2001)

Sharma, et al. Class I Major Histocompatibility Complex Anchor Substitutions Alter the Conformation of T Cell Receptor Contacts. *J. Biol. Chem.* 276(24): 21443-21449 (2001)

Respectfully Submitted,

Date: May 2, 2011

By: /Patrick J. Halloran/
Patrick J. Halloran
Reg. No. 41,053

Patrick J. Halloran, Ph.D., J.D.
3141 Muirfield Road
Center Valley, PA 18034
Tel: 610-984-4751
Fax: 484-214-0164